Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A.


Journal

Science (New York, N.Y.)
ISSN: 1095-9203
Titre abrégé: Science
Pays: United States
ID NLM: 0404511

Informations de publication

Date de publication:
26 02 2021
Historique:
received: 28 10 2020
accepted: 20 01 2021
pubmed: 27 1 2021
medline: 6 3 2021
entrez: 26 1 2021
Statut: ppublish

Résumé

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral proteins interact with the eukaryotic translation machinery, and inhibitors of translation have potent antiviral effects. We found that the drug plitidepsin (aplidin), which has limited clinical approval, possesses antiviral activity (90% inhibitory concentration = 0.88 nM) that is more potent than remdesivir against SARS-CoV-2 in vitro by a factor of 27.5, with limited toxicity in cell culture. Through the use of a drug-resistant mutant, we show that the antiviral activity of plitidepsin against SARS-CoV-2 is mediated through inhibition of the known target eEF1A (eukaryotic translation elongation factor 1A). We demonstrate the in vivo efficacy of plitidepsin treatment in two mouse models of SARS-CoV-2 infection with a reduction of viral replication in the lungs by two orders of magnitude using prophylactic treatment. Our results indicate that plitidepsin is a promising therapeutic candidate for COVID-19.

Identifiants

pubmed: 33495306
pii: science.abf4058
doi: 10.1126/science.abf4058
pmc: PMC7963220
doi:

Substances chimiques

Antiviral Agents 0
Coronavirus Nucleocapsid Proteins 0
Depsipeptides 0
EEF1A1 protein, human 0
Peptide Elongation Factor 1 0
Peptides, Cyclic 0
Phosphoproteins 0
RNA, Viral 0
nucleocapsid phosphoprotein, SARS-CoV-2 0
remdesivir 3QKI37EEHE
Adenosine Monophosphate 415SHH325A
Alanine OF5P57N2ZX
plitidepsin Y76ID234HW

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

926-931

Subventions

Organisme : NIAID NIH HHS
ID : HHSN272201400008C
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI120694
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI135990
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI122747
Pays : United States
Organisme : NCI NIH HHS
ID : F32 CA239333
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA221969
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA244550
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI135972
Pays : United States
Organisme : NIAID NIH HHS
ID : P01 AI063302
Pays : United States
Organisme : NIAID NIH HHS
ID : P50 AI150476
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI143292
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Références

Adv Exp Med Biol. 1995;380:499-506
pubmed: 8830530
Front Microbiol. 2018 Jun 29;9:1446
pubmed: 30008712
J Virol. 2009 Jul;83(13):6416-28
pubmed: 19369326
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Immunity. 2016 Jan 19;44(1):46-58
pubmed: 26789921
Nat Rev Microbiol. 2016 Aug;14(8):523-34
pubmed: 27344959
Virol J. 2015 Dec 22;12:221
pubmed: 26689940
Peptides. 2009 Jun;30(6):1074-81
pubmed: 19463739
Microbiol Mol Biol Rev. 2013 Jun;77(2):253-66
pubmed: 23699257
Nature. 2020 Jul;583(7816):459-468
pubmed: 32353859
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
J Virol. 2011 Jun;85(11):5669-73
pubmed: 21430047
N Engl J Med. 2021 Feb 11;384(6):497-511
pubmed: 33264556
Mar Drugs. 2011;9(6):1007-1023
pubmed: 21747745
Curr Protoc Microbiol. 2020 Sep;58(1):e108
pubmed: 32585083
Emerg Microbes Infect. 2020 Dec;9(1):2433-2445
pubmed: 33073694
JAMA. 2020 Sep 15;324(11):1048-1057
pubmed: 32821939
Sci Transl Med. 2017 Jun 28;9(396):
pubmed: 28659436
Cancer Chemother Pharmacol. 2009 Jun;64(1):97-108
pubmed: 18941750
Virology. 2006 Jul 20;351(1):180-7
pubmed: 16647731
Front Oncol. 2015 Apr 07;5:75
pubmed: 25905039
Invest New Drugs. 2012 Oct;30(5):1830-40
pubmed: 21887502
Nat Med. 2020 Apr;26(4):450-452
pubmed: 32284615
Front Immunol. 2020 May 12;11:1022
pubmed: 32574260
Oncotarget. 2019 Apr 12;10(28):2709-2721
pubmed: 31105871
Elife. 2015 Dec 10;4:
pubmed: 26651998
J Virol. 1986 Jan;57(1):328-34
pubmed: 2867230
Vet Microbiol. 2014 Aug 27;172(3-4):443-8
pubmed: 24974120
Lancet. 2020 May 16;395(10236):1569-1578
pubmed: 32423584
Future Oncol. 2019 Jan;15(2):109-120
pubmed: 30111169
Invest New Drugs. 2011 Dec;29(6):1406-13
pubmed: 20623160
Mol Ther. 2012 Dec;20(12):2268-81
pubmed: 22929662
bioRxiv. 2021 Feb 04;:
pubmed: 33501437
IDrugs. 2003 Mar;6(3):246-50
pubmed: 12789614
mBio. 2017 Apr 4;8(2):
pubmed: 28377531
Clin Cancer Res. 2006 Jun 15;12(12):3762-73
pubmed: 16778104
J Virol. 2008 Jun;82(11):5279-94
pubmed: 18367524
Proc Natl Acad Sci U S A. 2016 Mar 15;113(11):3048-53
pubmed: 26976607
J Clin Invest. 2013 Nov;123(11):4950-62
pubmed: 24135142
J Med Chem. 2020 Jun 11;63(11):5879-5955
pubmed: 32470302
Nat Protoc. 2019 Dec;14(12):3303-3332
pubmed: 31732721
BMJ. 2020 Jul 30;370:m2980
pubmed: 32732190
Am J Hematol. 2020 May;95(5):548-567
pubmed: 32212178
Ann Hematol. 2019 Sep;98(9):2139-2150
pubmed: 31240472
Virus Res. 2020 Oct 15;288:198137
pubmed: 32827627
Ann Oncol. 2006 Sep;17(9):1371-8
pubmed: 16966366
Nat Med. 2015 Dec;21(12):1508-13
pubmed: 26552008
PLoS One. 2014 Dec 05;9(12):e114447
pubmed: 25479059
Pharmacol Rev. 2006 Sep;58(3):621-81
pubmed: 16968952
J Virol. 2007 Jan;81(1):20-9
pubmed: 16928755
Angew Chem Int Ed Engl. 2015 Aug 24;54(35):10149-54
pubmed: 26179970
Nucleic Acids Res. 2020 Jul 2;48(W1):W488-W493
pubmed: 32246720
Clin Cancer Res. 2006 Jul 1;12(13):3997-4003
pubmed: 16818698
Cell. 2020 Apr 16;181(2):223-227
pubmed: 32220310
Cancer Res. 2008 Jul 1;68(13):5216-25
pubmed: 18593922
Nature. 2020 Jul;583(7816):469-472
pubmed: 32408336
Nature. 2020 Oct;586(7827):113-119
pubmed: 32707573
Nat Immunol. 2020 Nov;21(11):1327-1335
pubmed: 32839612
Science. 2020 Dec 4;370(6521):
pubmed: 33060197

Auteurs

Kris M White (KM)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. kris.white@mssm.edu nevan.krogan@ucsf.edu adolfo.garcia-sastre@mssm.edu.
Global Health Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Romel Rosales (R)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Global Health Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Soner Yildiz (S)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Global Health Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Thomas Kehrer (T)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Global Health Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Lisa Miorin (L)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Global Health Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Elena Moreno (E)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Global Health Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Sonia Jangra (S)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Global Health Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Melissa B Uccellini (MB)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Global Health Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Raveen Rathnasinghe (R)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Global Health Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Lynda Coughlan (L)

Department of Microbiology and Immunology and Center for Vaccine Development and Global Health (CVD), University of Maryland School of Medicine, Baltimore, MD, USA.

Carles Martinez-Romero (C)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Global Health Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Jyoti Batra (J)

Quantitative Biosciences Institute (QBI), University of California, San Francisco, CA 94158, USA.
J. David Gladstone Institutes, San Francisco, CA 94158, USA.
QBI Coronavirus Research Group (QCRG), San Francisco, CA 94158, USA.
Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94158, USA.

Ajda Rojc (A)

Quantitative Biosciences Institute (QBI), University of California, San Francisco, CA 94158, USA.
J. David Gladstone Institutes, San Francisco, CA 94158, USA.
QBI Coronavirus Research Group (QCRG), San Francisco, CA 94158, USA.
Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94158, USA.

Mehdi Bouhaddou (M)

Quantitative Biosciences Institute (QBI), University of California, San Francisco, CA 94158, USA.
J. David Gladstone Institutes, San Francisco, CA 94158, USA.
QBI Coronavirus Research Group (QCRG), San Francisco, CA 94158, USA.
Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94158, USA.

Jacqueline M Fabius (JM)

Quantitative Biosciences Institute (QBI), University of California, San Francisco, CA 94158, USA.
QBI Coronavirus Research Group (QCRG), San Francisco, CA 94158, USA.

Kirsten Obernier (K)

Quantitative Biosciences Institute (QBI), University of California, San Francisco, CA 94158, USA.
J. David Gladstone Institutes, San Francisco, CA 94158, USA.
QBI Coronavirus Research Group (QCRG), San Francisco, CA 94158, USA.
Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94158, USA.

Marion Dejosez (M)

Huffington Foundation Center for Cell-Based Research in Parkinson's Disease, Department of Cell, Developmental, and Regenerative Biology, Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

María José Guillén (MJ)

Research and Development Department, PharmaMar, 28770 Colmenar Viejo, Madrid, Spain.

Alejandro Losada (A)

Research and Development Department, PharmaMar, 28770 Colmenar Viejo, Madrid, Spain.

Pablo Avilés (P)

Research and Development Department, PharmaMar, 28770 Colmenar Viejo, Madrid, Spain.

Michael Schotsaert (M)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Global Health Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Thomas Zwaka (T)

Huffington Foundation Center for Cell-Based Research in Parkinson's Disease, Department of Cell, Developmental, and Regenerative Biology, Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Marco Vignuzzi (M)

Viral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, 75724 Paris Cedex 15, France.

Kevan M Shokat (KM)

Quantitative Biosciences Institute (QBI), University of California, San Francisco, CA 94158, USA.
QBI Coronavirus Research Group (QCRG), San Francisco, CA 94158, USA.
Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94158, USA.
Howard Hughes Medical Institute, University of California, San Francisco, CA 94143, USA.

Nevan J Krogan (NJ)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. kris.white@mssm.edu nevan.krogan@ucsf.edu adolfo.garcia-sastre@mssm.edu.
Quantitative Biosciences Institute (QBI), University of California, San Francisco, CA 94158, USA.
J. David Gladstone Institutes, San Francisco, CA 94158, USA.
QBI Coronavirus Research Group (QCRG), San Francisco, CA 94158, USA.
Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94158, USA.

Adolfo García-Sastre (A)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. kris.white@mssm.edu nevan.krogan@ucsf.edu adolfo.garcia-sastre@mssm.edu.
Global Health Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH